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Abstract 
Although EML4-ALK transforming fusion gene is represented in only 8% of non-small cell lung 
cancer (NSCLC) cases, its expression is partly responsive for the failure of current NSCLC 
treatments. Preventing secondary mutation of the ALK protein through direct gene manipulation 
could overcome NSCLC drug resistance.  
Method: In this study, we developed a gold nanoshell (HAuNs) drug carrier for delivery and 
selective photo-thermal release of genes that target ALK and microRNA-301 in NSCLC. 
Additionally, the densely-coated nanoshell adsorbed high amounts of the positively-charged 
anticancer drug doxorubicin (DOX), generating an exciting multidimensional treatment strategy 
that includes gene-, thermal- and chemo- therapy.  
Results: The ALK mRNA and microRNA-301 genes as the double targets exhibited the combined 
effect. The drug carrier system significantly improved the drug accumulation in tumor tissues due to 
the enhanced vascular permeability by photothermal effect, dense spherical structure and RGD 
peptide modification. 
In vitro and in vivo results demonstrated the multiple therapeutic effects of the gold nanoshell-based 
system was better than the monotherapy. 
Conclusion: The above results indicated the gold nanoshell-based system would be a promising 
translational nano-formulation platform for effective treatment of EML4-ALK-positive NSCLC. 
Key words: EML4-ALK, gold nanoshell, gene therapy, hyperthermia, chemo-therapy. 
Introduction 
Lung cancer is the first leading cause of death 
among different cancer types. In the past 10 years, the 
morbidity and mortality of lung cancer worldwide 
has continued to increase, clearly becoming a major 
threat to public health [1]. Each year, about 1.5 million 
new cases of lung cancer are reported, and 80 % of 
these cases are diagnosed as non-small cell lung 
cancer (NSCLC) [2]. Among the different kinds of 
NSCLC, those expressing the echinoderm 
microtubule-associated protein-like 4-anaplastic 
lymphoma kinase (EML4-ALK) fusion gene mutation 
are among the most malignant types [3]. 
Approximately 8% of NSCLC patients are EML4-ALK 
positive, and it is estimated that approximately 70,000 
new cases of EML4-ALK gene-positive lung cancer 
will occur all over the world in one year. [4].  
  EML4-ALK mutations show a strong 
exclusiveness in NSCLC patients, which means this 
kind of mutation occurs alone without mutations of 
other driving genes. For example, EML4-ALK fusion 
gene scarcely coexists with EGFR and other 
mutations. As a result, in the NSCLC patients 
expressing EML4-ALK mutations, treatment with 









prognosis. Consequently, EML4-ALK fusion gene has 
become a unique therapeutic target for the 8% of 
NSCLC patients expressing EML4-ALK mutations, 
with great clinical significance [5]. The ALK-targeted 
small molecule drug crizotinib and its derivatives 
have shown encouraging results in the initial 
treatment of ALK-positive NSCLC patients. However, 
these ALK-targeted drugs have been shown to induce 
mutations of ALK kinase and increase ALK gene copy 
number with continuous treatment, resulting in the 
occurrence of drug resistance [6]. Patients treated with 
crizotinib or crizotinib-based drugs showed acquired 
drug resistance to different extents after 8 months, 
leading to tumor recurrence [6-8]. Gene therapy for 
target proteins can be an effective strategy for 
suppressing protein expression and can significantly 
improve therapeutic efficacy. Moreover, gene therapy 
may prevent the occurrence of secondary drug 
resistance caused by drug-induced mutations [9,10]. 
Gene therapy inhibits the expression of target 
proteins by suppressing the mRNA of the target 
protein. Small interfering RNA (siRNA) is a 
promising strategy to inhibit the target ALK mRNA 
for cancer therapy [11-13]. Takezawa et al. reported 
that the over-expression of ALK protein could activate 
both JAK/STAT3 and RAS/ERK signaling pathways 
to enhance expression of the anti-apoptosis gene 
Survivin and inhibit the tumor suppressor gene Bim, 
promoting the development of tumor cells in the 
EML4-ALK fusion mutant NSCLC [14]. Accordingly, 
down-regulation of ALK mRNA expression could 
increase the expression of Bim to induce tumor cell 
apoptosis. However, inhibiting ALK mRNA alone 
could hardly achieve an ideal therapeutic effect 
because intracellular protein expression is a complex 
process that is regulated by cross-effects of multiple 
signaling pathways [15]. Recently, researchers have 
paid much attention to the study of microRNA’s 
function. A recent study showed that miR-301a is 
involved in PC progression. Lee et al. investigated 
aberrant miRNA expression in PC, and showed 
increased levels of miR-301a in PC tissues [16]. Lu et 
al. certified that miR-301a downregulated 
NF-kB-repressing factor (Nkrf) and elevated NF-kB 
activation [17]. Chen et al. revealed that the presence 
of microRNA-301 in pancreatic cancer cells 
down-regulates Bim expression, thereby promoting 
the proliferation of tumor cells [18,19]. Hence, we 
selected microRNA-301 as another target to amplify 
the treatment outcome. 
In gene therapy, a specific strategy for gene 
transfection is indispensable to introduce foreign 
genes into target cells. Gold nanoshell is a novel type 
of biocompatible nano-carrier, which is currently 
under investigation as a hyperthermia agent for 
cancer treatment in a phase II clinical trial [20]. The 
large surface area of gold nanoshell presents the 
opportunity to upload multiple genes and drugs 
simultaneously to improve therapy. The unique 
spatial structure formed by the densely coated 
spheroidal particles can prevent the biomolecules 
from being rapidly degraded by enzymes in the blood 
circulation [21-23]. Combined with the good 
optical-to-thermal conversion efficiency of gold 
nanoshell, increased temperature can break the 
thiol-Au bond upon NIR light irradiation, which can 
trigger subsequent release of the siRNAs and 
chemotherapeutic agents for controlled therapy 
[24-31]. In addition, the photothermal effect could 
enhance local blood perfusion and vascular 
permeability in tumors, resulting in improved 
accumulation and penetration of the gold 
nano-system into the tumor microenvironment [32]. 
Simultaneously, the surface of the gold nanoshell can 
be modified with tumor-targeting ligands, 
transforming the nano-carrier into a tumor-avid 
nanoparticle [33-37]. Furthermore, the dense spherical 
structure of the gold nano-system may facilitate its 
cellar uptake [38]. With the active targeting ligand 
RGD peptide and its dense spheroidal structure, a 
high concentration of HAuNs accumulated in cancer 
cells. Interestingly, we found that nanoshells densely 
coated with siRNA could absorb more of the 
positively charged anticancer drug doxorubicin 
(DOX), allowing for combinatory therapy. 
Concurrently, the heat caused by NIR irradiation on 
the gold nanoparticles could damage the tumor tissue 
and cells at a macroscopic level, while the gene- and 
chemo-therapy could inhibit the cells in a molecular 
level. Therefore, the treatment should exhibit a 
synergistic effect with the combination of gene 
therapy, chemotherapy and hyperthermia therapy.  
Herein, we established a drug delivery system 
based on the gold nanoshell DOX@siRNA@HAuNs to 
explore an alternative effective treatment paradigm 
for EML4-ALK fusion mutant NSCLC. Inhibition of 
ALK and miR-301 exhibited a synergistic apoptotic 
effect on EML4-ALK cells. The drug carrier system, 
DOX@siRNA@HAuNs, showed many remarkable 
abilities, such as high drug-loading capacity, siRNA 
sequence protection, and tumor targeting ability. The 
amplified synergistic therapeutic effect was 
demonstrated both in vitro and in vivo, indicating the 
DOX@siRNA@HAuNs drug carrier system is a 
promising nanoplatform for EML4-ALK NSCLC 
treatment.  
 





Materials and methods 
Materials 
Cobalt chloride hexahydrate, chloroauric acid 
(HAuCl4), trisodium citrate dehydrate, and sodium 
borohydride were purchased from Guoyao Reagent 
Corporation (Shanghai, China). Dithiothreitol (DTT) 
and glutathione (GSH) were purchased from 
Sigma-Aldrich Inc. (USA). Sulfhydryl polyethylene 
glycol, and RGD peptide were purchased from 
Shanghai Sangon Biotech, Inc. EML4-ALK mutation 
cells H2228, normal liver cells L02 and NSCLC A549 
(ALK fusion-negative, as control cells) cells were 
obtained from KeyGen Biotech. (Nanjing, China). 
Athymic nude mice were purchased from SLAC 
Laboratory Animal Co. Ltd. (Shanghai, China). 
Bovine serum albumin and cell culture media were 
purchased from Sangon Biotech (Shanghai) Co., Ltd. 
The siRNAs and nonsense sequences with or without 
the modification of -SH and FITC were purchased 
from Sangon Biological Engineering Technology & 
Co. Ltd. (Shanghai, China).  
Synthesis of RGD @siRNA@HAuNs drug 
delivery system  
Hollow gold nanoshells (HAuNs) were prepared 
by the previously reported method [23]. Stable 
suspensions of silver nanoparticles were synthesized 
in minutes using an aqueous solution of sodium 
citrate and silver nitrate, and the addition of sodium 
borohydride accelerated the chemical reaction. The 
reaction proceeded at 60 °C. Larger silver particles 
were formed from these nanoparticles by reducing 
additional silver nitrate in the presence of 
hydroxylamine hydrochloride; the nanoparticles act 
as nuclei for further growth. Then, the silver 
nanoparticles were converted into hollow gold 
nanoshells (HAuNs) by adding HAuCl4 directly to the 
as-grown nanoparticle solution. Subsequently, 
multiple copies of siRNA were conjugated to the 
surface of the HAuNs either directly or supported by 
a single strand DNA linker through a quasi-covalent 
(Au−S) bond. Finally, moderate DOX accumulated on 
the surface of the prepared siRNA@HAuNs by 
electrostatic adsorption, forming the DOX@siRNA@ 
HAuNs drug delivery system. The nanoparticles were 
stored at 4 ℃. For the fabrication of the combinatory 
drug delivery system, Thiol-PEG-COOH was used as 
a stabilizer as well as a linker/spacer to attach various 
agents to HAuNs via one end of the thiol group. The 
amino group of the targeting peptide RGD was 
coupled with the carboxyl group of thiol-PEG-COOH 
(amount ratio RGD/PEG=1:1) through EDC reaction 
catalyzed by NHS.  
Nucleic acid electrophoresis assay of siRNA 
protection 
To investigate the protective effect of 
siRNA@HAuNs, delivery vectors were incubated 
with 0.25% RNase A for 0.5 h. Then, the sample was 
loaded on a 1% agarose gel containing 0.01% Gel-Red 
and run at 90 V for 30 min. To release the loaded 
siRNA, the samples were treated with heparin at a 
dose of 1 U/mg siRNA in DEPC-treated water. 
Endosomal escape of siRNA 
Approximately 3×105 H2228 cells were seeded 
onto confocal dishes and incubated overnight at 37 °C. 
Cells were then treated with siRNA@HAuNs (siRNA 
with FITC). After incubation for 4 h, Lyso-Tracker Red 
was added and incubated for 0.5 h. Then, the 
intracellular fluorescence was visualized using 
confocal laser scanning microscopy (CLSM). 
Laser-induced DOX release 
Approximately 3×105 H2228 cells were seeded 
onto confocal dishes and incubated overnight at 37 °C. 
Cells were then treated with RGD@DOX@HAuNs 
(siRNA without FITC) and imaged before or after 
laser treatment (785 nm light irradiation, 1.2 W/cm2, 
for 5 min). After incubation for 4 h, Hochest was 
added and incubated for 0.5 h. Then, the intracellular 
fluorescence was visualized using CLSM. 
In vitro therapeutic effect  
Cellular toxicity of nanoshells and the 
DOX@siRNA@HAuNs drug delivery system in 
different cell lines and conditions was measured by 
MTT assay. Cell apoptosis caused by the 
DOX@siRNA@HAuNs drug delivery system with 785 
nm laser was detected by flow cytometry and LCSM. 
In vivo therapeutic efficacy 
All animal experiments were carried out in 
compliance with the Animal Management Rules of 
the Ministry of Health of the People's Republic of 
China (document NO. 55, 2001) and the guidelines for 
the Care and Use of Laboratory Animals of China 
Pharmaceutical University. Nude mice bearing 
H2228-derived tumors were randomly assigned to 1 
control group and 5 experimental groups (n=5) when 
the tumor diameter reached 0.5 cm. Mice in the 
control group were injected with PBS while the 
experimental groups were injected with DOX, bare 
nanoshells and DOX@siRNA@HAuNs. 12 h 
post-injection, different therapeutic schedules were 
performed on each experimental group: (1) Dox 
injection without light irradiation; (2) 785 nm light 
irradiation (1.2 W/cm2) for 5 min with nanoshell 
injection; (3) 785 nm light irradiation (1.2 W/cm2) for 5 





min with DOX@siRNA@HAuNs. Tumor sizes and 
body weights were measured every other day. Tumor 
volumes were measured using calipers and calculated 
according to the following formula: size (mm3) = 
length (mm) × width (mm)2/2. All mice were 
sacrificed and the tumors were collected 14 days after 
treatment.  
Results and discussion 
Function of ALK siRNA and miRNA-301 
inhibitor in H2228 cells 
We used western blot to confirm the function of 
the double gene therapy targeting ALK and 
miRNA-301 in H2228 cells. Treatment of the cells with 
ALK siRNA significantly down-regulated the 
expression of ALK and the phosphorylation level of 
downstream protein p-ERK in H2228 cells, inhibiting 
cell proliferation (Figure 1A). In addition, ALK siRNA 
increased the expression of apoptotic protein Bim. The 
results also showed that the miRNA 301 inhibitor 
improved Bim expression, while miRNA 301 mimics 
suppressed Bim activity in H2228 cells. Interestingly, 
the ALK siRNA treatment had little or no influence on 
Bim expression in A549 cells where the ALK level was 
in the normal range (Figure 1B). These results indicate 
that the effect of ALK siRNA is cell-dependent and 
the ALK siRNA-based treatment would be specific. In 
addition, both ALK siRNA and miRNA 301a inhibitor 
are able to increase the expression of Bim in H2228 
cells. Therefore, simultaneous inhibition of the 
dual-targets, ALK mRNA and miRNA 301a, could 
exert a synergistic effect on the survival of EML4-ALK 
fusion mutation lung cancer. We compared the cell 
viability of EML4-ALK mutation H2228 cells and ALK 
fusion-negative A549 cells after siRNA transfection 
with Lipofectamine (Figure 1C). We found that the 
cell viability of H2228 cells (33.1%) was much lower 
than that of A549 (81.3%) when the cells were 
incubated together with ALK siRNA and 
microRNA-301 (p<0.05). This finding suggests that 
the double target gene therapy amplified its 
therapeutic effect in cancer cells. The fact that the 
normal NSCLC A549 cells survived over 80% in each 
group indicates that this combination therapy is 
selective to cancer cells expressing higher levels of 
EML4-ALK mutation than ALK fusion-negative cells.  
We next postulated that apoptosis induction 
may mediate the cytotoxic effect of the combination 
therapy. To test this hypothesis, the extent of cell 
apoptosis following different treatments was 
analyzed using flow cytometry (FCM). After 
simultaneously transfecting cells with both siRNAs, 
the apoptosis rate of H2228 cells increased to 44.1%, 
which was higher than the effects of ALK siRNA 
(25.7%) or microRNA-301 (25.1%) alone (Figure 
1D-E). The ensemble of these results lends strong 
support to the development of a dual gene targeting 
strategy for treating EML4-ALK NSCLC.  
Synthesis and Characterization of 
RGD@siRNA@DOX@HAuNs drug delivery 
system  
The structure of RGD@siRNA@DOX@HAuNs 
and the mechanism of target selection are illustrated 
in Scheme 1. The transmission electron microscopy 
(TEM) image of the prepared RGD@siRNA@DOX@ 
HAuNs (Figure 2A) shows a core-shell structure of 
the drug carriers. The mean hydrated diameters of the 
nanoshell and the sequence-coated shell are ~25 nm 
and ~35 nm, respectively (Figure S1A-B) and the PDI 
value was ~0.06. Analysis of the photothermal 
conversion showed that laser irradiation can quickly 
and significantly increase the temperature from 25 °C 
to ~53 °C within 5 min (Figure 2B).   
The UV-visible absorption spectra of various 
components (Figure S1C) confirmed the successful 
conjugation of siRNA (absorption peak @215 nm), 
DOX (absorption peak @480 nm), and HAuNs 
(absorption peak @800 nm), with a Zeta potential of 
-13 mV for HAuNs (Figure S1D). Modification of the 
positively charged RGD peptide slightly changed the 
Zeta potential to -12 mV. In particular, uploading the 
negatively charged siRNA greatly enhanced the 
negative potential (-20 mV), favoring enhanced 
adsorption of the positively charged anticancer drug 
DOX. The siRNA was loaded onto the HAuNs by 
Au-S bonds, not by electrostatic adsorption, so the 
negative potential would not hinder uploading of 
siRNA in this study. The fluctuation in Zeta potential 
indicates the success of each reaction process and 
production of the novel drug delivery system 
RGD@siRNA@DOX@HAuNs.  
 The correlation of siRNA loading with DOX 
adsorption was also investigated. We found that 
nanoshells with increased coating of negative siRNA 
sequence (siRNA@ HAuNs) could adsorb more DOX, 
with a maximum of 20% DOX loading (the amount of 
DOX was calculated by the ultraviolet absorption 
spectrum of DOX in the solution). At low 
concentrations, there was a linear relationship 
between the loading quantities of siRNA and DOX. 
Specifically, we found that the optimal siRNA loading 
concentration to achieve 20% of DOX loading was 200 
nM (Figure 2C). The laser-triggered release of 
RGD@DOX@siRNA@HAuNs as a whole was 
analyzed at different illumination times (Figure 2D). 
Within 5 min of laser light exposure, there was a 
linear relationship between laser duration (minutes) 
and cumulative drug release (%). In addition, a 5 min 





light exposure was sufficient to trigger the release of 
over 80% of siRNA and DOX, indicating that drug 
release from the HAuNs drug carrier could be 
controlled by light illumination.  
The stability and drug release properties of 
HAuNs before and after PEG coupling were 
characterized at different pH values and different 
concentrations of salt solution (Figure S2A-D). The 
results show that the cumulative drug release of both 
siRNA and DOX were low under different conditions, 
with the exception of DOX release in acidic 
environments. This unique property might enhance 
drug release in the tumor microenvironment, which is 
known to be more acidic than surrounding tissue (pH 
value : blood and healthy lung tissue 7.35~7.45; tumor 
lung tissue 6.5~7.0).  
 
 
Figure 1. The mechanism of treatment target selection and the synergistic effect of gene silencing. (A) Western blot assay after ALK siRNA, miR-301 
inhibitor and miR-301 mimics transfection in H2228 cells. (B) Western blot assay after ALK siRNA transfection in A549 cells. (C) Survival of cells treated under the 
conditions in (A-B) determined by MTT assay. (D) Apoptosis of cells treated under the above conditions assayed by AV-PI kit. (E) Quantitative analysis of (D). Data 
are given as mean ± SD (n=5). *, P<0.05. 






Scheme 1. Schematic illustration of the nanostructure design and the target selection mechanism of gene therapy. 
 
Figure 2. Characterization of the RGD@siRNA@DOX@HAuNs drug carrier system. (A) Transmission electron microscopy (TEM) characterization of 
the drug carrier system. (B) The photothermal conversion of HAuNs with NIR laser irradiation (C) Relationship between the amount of conjugated siRNA and DOX 
adsorption (siRNA-FITC: 520 nm, DOX: 585 nm). (D) Relationship between drug release and light irradiation time (siRNA-FITC: 520 nm, DOX: 585 nm). Data are 
given as mean ± SD (n=5). *, P<0.05. 





Properties of the RGD@DOX@siRNA@ 
HAuNs drug delivery system 
siRNA sequence protection ability   
The nucleic acid electrophore diagram (Figure 
3A) depicts the stability of siRNA in a solution of the 
hydrolytic enzyme (Rnase 1). siRNA and siRNA@ 
HAuNs exhibited bright spots in the electrophore lane 
(lane a\b) without Rnase 1 incubation. When ALK 
siRNA itself was incubated with Rnase 1, no signal 
was detected in the lane, implying complete 
degradation of the siRNA. However, upon 
attachment of ALK siRNA to the HAuNs, a bright 
signal was observed in the Rnase 1 and serum 
solution, indicating that the nanoshell protected the 
coated siRNA. As expected, the siRNA sequence was 
detached from the shell after NIR irradiation and 
degraded by the Rnas I enzyme, leading to 
disappearance of the signal in the electrophore lane. 
These results support the siRNA protective ability of 
the HAuNs carrier.  
Improved transfection efficiency   
Figure 3B shows a comparison of the gene 
transfection efficiency of HAuNs and the widely used 
commercial Lipofectamine reagent Lip2000. After 
incubation with siRNA@HAuNs, the expression of 
ALK in H2228 cells was significantly suppressed 
(28.8%), while it remained at 41.2% with Lip2000 
transfection (p<0.05). The results indicated that 
HAuNs are an ideal siRNA vector with better gene 
transfection efficiency than Lipofectamine.  
 
 
Figure 3. The properties of the RGD@siRNA@DOX@HAuNs drug carrier system. (A) The nucleic acid electrophore diagram for various conditions. 
(B) Relative mRNA expression of EML4-ALK determined by real-time PCR. (C) Laser confocal microscopy image of endosomal escape of 
RGD@siRNA@DOX@HAuNs before and after laser illumination; red: lysosome, green: siRNA-FITC, and yellow: colocalization of siRNA -FITC and endolysosome. 
(D) Laser confocal microscopy image of DOX release after laser illumination; red: DOX, blue: hochest. Data are given as mean ± SD (n=5). *, P<0.05. 






The localization of siRNA@HAuNs in H2228 
cells was imaged by confocal microscopy (Figure 3C). 
Before NIR irradiation, the siRNA@HAuNs (green 
fluorescence) were well colocalized with endosomes 
(red fluorescence), indicating that siRNA@HAuNs are 
in the endosomal compartment. However, after NIR 
irradiation, the green fluorescence separated from the 
red, suggesting that siRNA@HAuNs escaped from 
the endosome, supporting the endosomal escape 
ability of HAuNs with laser-induced heat generation. 
It is known that nanoparticles may initially enter the 
endosome after cell uptake and then be transferred to 
the lysosome, where the particles and loaded drugs 
are degraded. To avoid this fate, the nano-carriers 
should be designed to quickly escape from lysosomes 
to allow the effective drug to reach the target. For this 
nanoshell-based drug system, NIR irradiation 
induced photothermal effects, leading to permeabil-
ization of endosomes by the increased temperature.   
DOX release 
To further explore the control of DOX release 
from the drug delivery system, DOX@siRNA@ 
HAuNs were irradiated at the cellular level using a 
laser confocal microscope (Figure 3D). DOX and 
nuclear dye fluorescence were false-colored red and 
blue, respectively. The result shows that the red and 
blue fluorescence did not overlap without irradiation, 
indicating that DOX did not enter the nucleus because 
most DOX was adsorbed onto DOX@siRNA@HAuNs. 
However, after light treatment, drug release was 
evidenced by red and blue fluorescence overlap, 
showing that a large amount of DOX was released 
from DOX@siRNA@HAuNs and entered the nucleus. 
These results also confirmed that DOX release can be 
achieved by 785 nm laser irradiation. The reason that 
DOX could be released by laser irradiation is mainly 
by the breakage of siRNA from HAuNs (Au-S) and 
HAuN collapse, which leads to a change in electric 
potential [25,26]. 
Tumor-targeting ability of the 
RGD@DOX@siRNA@HAuNs drug delivery 
system 
Figure 4A compares the cellular uptake of the 
nanoshell system with and without RGD modi-
fication. RGD peptide conjugation was found to 
significantly improve the efficiency of drug uptake by 
H2228 cells. At a similar incubation time (30 min), the 
RGD-modified group showed stronger green 
fluorescence (FITC-labelled siRNA) than the 
non-RGD group. Quantitative analysis of HAuNs- 
associated fluorescence intensities demonstrated that 
the RGD conjugation significantly increased (p<0.05) 
the cellar uptake of the drug delivery system (more 
than double growth) (Figure 4B). For further 
evaluating the cellar uptake of gold nanoparticles 
coated with different components, dark field 
microscopy was performed. The intensity of white 
light represents the amount of nanoparticle in the cells 
(Figure 4C). As anticipated, RGD@siRNA@HAuNs- 
treated cells exhibited the strongest light signal in 
cells compared to the weakest and low signals found 
in free HAuNs- and siRNA@HAuNs-incubated cells. 
This result confirmed that siRNA coating could 
enhance the cell uptake of the nanoparticles and that 
the RGD peptide conjugation can further improve the 
cell targeting capability of siRNA@HAuNs. Further, 
inductively coupled plasma-mass spectrometry 
(ICP-MS) was applied to quantitatively determine the 
elemental gold content in the H2228 cells (Figure 4D). 
The intracellular content of Au was 3×104/per cell for 
HAuNs incubation, 1×105/per cell for siRNA@ 
HAuNs-treated cells and 6×105/per cell for RGD@ 
siRNA@HAuNs-treated cells. The quantitative ICP- 
MS results were consistent with the results of dark 
field microscopy, further validating the enhanced 
targeting efficiency provided by the RGD peptide. 
To investigate the bio-distribution and 
tumor-targeting ability of RGD@DOX@siRNA@ 
HAuNs in vivo, near-infrared fluorescence imaging 
was performed in H2228 tumor-bearing nude mice. 
MPA, a hydrophilic near-infrared fluorescence dye 
with similar molecular weight as DOX, was used to 
replace the DOX for NIR imaging. We found that 
RDG@MPA@siRNA@HAuNs distributed throughout 
the body within 30 min, then gradually accumulated 
in the tumor site up to 12 h post-injection (Figure 4E). 
As expected, no fluorescence signal was observed at 
the tumor site in the MPA administration group. The 
result demonstrated the favorable tumor-targeting 
ability of the nanoshell-based drug carrier system. For 
exploring the blood perfusion of tumor tissues upon 
photothermal stimulation, the H2228 tumor bearing 
mice with different treatments were sacrificed and the 
tumor sections were analyzed by hematoxylin and 
eosin (H&E) staining (Figure 4F). The blood perfusion 
and extravasation were elevated upon laser 
irradiation of the gold nanoshells, confirming the 
enhanced blood permeability via thermal effects. In 
contrast, less blood signal was observed in the group 
without laser exposure. The data suggest that 
additional antitumor drug will be effectively 
delivered to the cancerous tissue through the blood 
stream after NIR irradiation. To further investigate 
the tumor delivery abilities, histological sections of 
different organs (tumor, heart, liver, spleen, and 
kidney) were analyzed by confocal microscopy. As 
seen in Figure 4G, free DOX distributed in all the 





organs, indicating the potential for severe toxicity to 
normal organs. For mice administrated with the 
RGD-modified nanoshell system, strong DOX signal 
was observed in the tumor tissue, while low signals 
were exhibited in other tissues. These results show 
that the RGD@DOX@siRNA@HAuNs have high 
affinity to tumor tissue. Moreover, the tumor 
accumulation of DOX was greatly improved by the 
laser irradiation, confirming the enhanced 
permeability of the tumor blood vessels by the 
photothermal effect and reduced accumulation of 
nano-drugs in other vital organs.  
In vitro therapy of RGD@DOX@siRNA@ 
HAuNs  
To investigate the cell toxicity of the HAuN 
itself, a range of concentrations of HAuNs was 
cultured with H2228 (Figure 5A). The results showed 
that the H2228 tumor cells and L02 normal cells did 
not exhibit obvious cytotoxicity until the 
concentration of HAuNs exceeded 1.5 nM, which was 
used in further studies.  
The laser duration (illumination time) is an 
important factor for this treatment. To identify the 
optimal treatment time, different illumination time 
gradients were tested with RGD@DOX@siRNA@ 
HAuNs, and the HAuNs were used as control group. 
The results revealed that within 5 min irradiation, the 
cell survival rate of the two groups were 23% and 47% 
(Figure 5B) (p<0.05). Interestingly, beyond 5 min 
irradiation, there was no obvious additional impact 
on the cell survival. Thus, 5 min was the optimal time 
for the therapy. Equally important, the treatment 
effect of the RGD@DOX@siRNA@HAuNs group was 
obviously better than that of the HAuNs group after 
laser irradiation (cell survival rate less than double 
reduce, p<0.05).  
The therapeutic efficacies between single 
treatment and combined treatment were also 
 
Figure 4. The tumor-targeting ability of the RGD@siRNA@DOX@HAuNs drug carrier system. (A) Laser confocal microscopy images of the 
cell-uptake ability of the nano-carrier with or without RGD modification; green: siRNA-FITC, blue: Hoechst. (B) The quantification of the laser confocal microscopy 
images in (A). (C) Dark field microscopy images of H2228 cells with HAuNs, siRNA@HAuNs and RGD@siRNA@HAuNs incubation. (D) ICP-MS assay of HAuNs, 
siRNA@HAuNs and RGD@siRNA@HAuNs in H2228 cells. (E) NIR images of MPA and RGD@siRNA@MPA@HAuNs dynamics in H2228 tumor-bearing nude 
mice at different times after intravenous injection. (F) H&E stained sections of H2228 tumors after RGD@siRNA@MPA@HAuNs treatment and laser irradiation; 
Laser-: treatments without NIR laser irradiation; Laser+: treatments with NIR laser irradiation. (G) Laser confocal microscopy images of tissue samples of tumor, 
heart, liver, spleen and kidney from different treatment groups; red: fluoresce of DOX. Data are given as mean ± SD (n=5). *, P<0.05. 
 





compared in our study (Figure 5C). Using an in vitro 
model, we found that the cell survival rate of each 
group was 42% (HAuNs+Laser), 36.5%(DOX), and 
20% (RGD@DOX@siRNA@HAuNs). These results 
confirmed our hypothesis that the combined group 
(compared with the single treatment: photothermal 
induced by HAuNs, DOX, siRNA effect in figure 1C) 
displayed the best treatment effect through a 
multidimensional cooperative treatment effect that 
includes hyperthermia, chemotherapy, and gene 
therapy.  
The ability of drug carriers to induce cell 
apoptosis was also evaluated using a AV-PI kit 
(Figure 5D). Flow cytometry results showed that the 
apoptosis rate of the RGD@DOX@siRNA@HAuNs 
group reached 69.1%, while that of the HAuNs group 
was only 0.267%. Further, confocal microscopy 
(Figure 5D) revealed that most cells were already in 
the late stage of apoptosis (red and green colors 
represent the cells in the stage of apoptosis) after 
treatment by RGD@DOX@siRNA@HAuNs + Laser, 
indicating the excellent therapeutic efficacy of 
RGD@DOX@siRNA@HAuNs at the cellular level. The 
cell apoptosis rates caused by each monotherapy 
(only ALK siRNA or only micRNA-301 inhibitor) 
were less than the designed final drug system (Figure 
S3).  
Using Calcein-AV and PI to stain live and dead 
cells, respectively, we show that most of the cells 
treated with laser or HAuNs were not damaged 
(Figure 5E). In contrast, the cells within the semicircle 
dashed line (Figure 5Ed) were almost dead under the 
HAuNs and laser treatment, while cells in the 
unexposed area outside the semicircle were still alive. 





Figure 5. Treatment efficacy of RGD@siRNA@MPA@HAuNs at a cellular level. (A) Survival rate of H2228 cells and L02 cells after incubating with 
different concentrations of bare HAuNs. (B) Survival rate of H2228 cells after incubating with bare HAuNs and RGD@siRNA@MPA@HAuNs with different laser 
duration times. (C) Survival rate of H2228 cells treated under the above conditions determined by MTT assay. (D) Flow cytometry and laser confocal microscopy 
examination of the apoptosis of H2228 cells after irradiation of RGD@siRNA@MPA@HAuNs. (E) Laser confocal microscopy of photothermal therapy of HAuNs 
in H2228 cells; viable cells were stained green with Calcein-AV, and dead cells were stained red with PI. Cells were treated with only the dye (a) as the control group, 
HAuNs without irradiation (b), irradiation only (c) and HAuNs with irradiation (d). Data are given as mean ± SD (n=5). *, P<0.05. 
 





In vivo antitumor therapeutic efficacy of 
RGD@DOX@siRNA@HAuNs  
The in vivo antitumor efficacy of RGD@DOX@ 
siRNA@HAuNs was further evaluated in a nude 
mouse model (H2228 cells subcutaneous transplan-
tation tumor). The tumor growth rate, survival rate 
and the body weight of the mice under different 
treatments were monitored (Figure 6). Tumors in the 
control mice treated with saline grew faster than the 
treated groups (Figure 6A-C). The RGD@DOX@ 
siRNA@HAuNs treatment group exhibited the 
optimal inhibition effect of tumor growth. The growth 
of H2228 tumor was inhibited at a rate of 65% after the 
administration of RGD@DOX@siRNA@HAuNs+ 
laser, which is higher than that of the free HAuNs + 
laser (43%) and free DOX (45%) groups. Furthermore, 
the weight of mice bearing H2228 tumors in the 
RGD@DOX@siRNA@HAuNs group was stable 
compared with the DOX- and HAuNs-treated groups 
(Figure 6D). The 22-day survival rate of mice in the 
RGD@DOX@siRNA@HAuNs group was 80%, a much 
better outcome than the free HAuNs (40%) and free 
DOX (40%) groups, whereas all the mice in the saline 
group died by day 16 (Figure 6E). These results 
demonstrate the efficacy of multimodal nanoparticle 
over the over the free DOX and photothermal (free 
gold nanoshell) was realized by the RGD@DOX@ 
siRNA@HAuNs drug carrier system. 
To further investigate toxicity on the major 
organs of mice and the anti-tumor effects of the 
different treatments, histological examination was 
conducted. The results showed that the number of 
tumor cells in the saline-injected group was 
significantly higher than that in the other two groups 
(Figure 6F). The tumor cells were in a dense mitotic 
condition, suggesting that the tumor cells were 
primed for continued rapid proliferation. Histopatho-
logical examination of tumor tissues in the 
RGD@DOX@siRNA@HAuNs-treated group revealed 
more pronounced pathological changes than that of 
the DOX-treated group. Clearly, the tumor treatment 
efficacy of RGD@DOX@siRNA@HAuNs is superior to 
that of free DOX in this study. Meanwhile, the 
DOX-injected group showed more severe cardio-
toxicity, liver toxicity and renal toxicity. In contrast, 
the organ toxicity in the RGD@DOX@siRN @HAuNs 
group was mild. The reason for this observation can 
be attributed to the tumor-targeting drug carrier 
system that efficiently delivered and retained more 
drugs (DOX and siRNA) in the tumor tissue in vivo, 
thereby enhancing the treatment efficacy with 
minimal side effects. Finally, the ALK and Bim 
expressions in the tumor tissue (RGD@DOX@ 
siRNA@HAuNs) were tested, and the results 
exhibited that the expressions of ALK and Bim could 
be inhibited effectively (Figure S4). 
 
 
Figure 6. Antitumor therapeutic efficacy of RGD@DOX@siRNA@HAuNs on tumor-bearing mice. (A) Images of mice with tumors treated as 
indicated. (B) Tumor volumes of mice bearing H2228 tumors under different treatments as indicated. (C) Tumor weights of mice bearing H2228 tumors from the 
different treatment groups on the 16th day after injection. (D) Body weights of mice bearing H2228 tumors in the different groups. (E) The 16-day survival rates of 
mice after different administrations. F, Analysis of the experiment tumor bearing mice tissue. A, H&E stained images of tumor, heart, liver, spleen and kidney sections 
collected from different treatment groups. Data are given as mean ± SD (n=5). *, P<0.05. 






 In this study, we designed and developed a 
drug carrier system RGD@DOX@siRNA@HAuNs 
targeted specifically for the treatment of EML4-ALK 
gene fusion NSCLC. The multiple impressive qualities 
of the new multidimensional nanoplatform includes 
the high drug loading rate, controlled drug release, 
and selective tumor targeting. The combination of 
gene therapy, chemotherapy and thermal therapy 
(siRNA, DOX, photothermal induced by free gold 
nanoshell) exhibited a cooperative effect that 
improved the treatment of EML4-ALK gene fusion 
NSCLC in vitro and in vivo. This study provides a 
promising strategy for the treatment EML4-ALK gene 
fusion NSCLC. 
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